4D Path

4D Path has developed the patented QPOR™ Platform to directly measure and quantify cell cycle deregulations and tumor microenvironment dynamics from routine biopsy images. The technology enables precision treatment selection by predicting patient responses to therapies across multiple tumor types. The company’s lead product, the Q-Plasia OncoReader Breast, received FDA Breakthrough Device Designation based on its potential to improve diagnostic accuracy over existing alternatives. Clinical collaborations have demonstrated improved patient stratification and therapeutic response prediction in breast cancer and advanced melanoma trials. The software currently has research-use-only status.